The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Khabirov F.A.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Khaĭbullin T.I.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Granatov E.V.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Shakirzianova S.R.
GAUZ «Republic clinical neurology center», Kazan, Russia
Babicheva N.N.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Kochergina O.S.
Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia
Rakhmatullina E.F.
Neurology and manual therapy department of state medical academy, Kazan, Russia
Akhmedova G.M.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Aver'ianova L.A.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Yakupov M.A.
Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia
Sabirov Zh.F.
Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia
The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3): 18‑26
Views: 4123
Downloaded: 89
To cite this article:
Khabirov FA, Khaĭbullin TI, Granatov EV, et al. . The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate. S.S. Korsakov Journal of Neurology and Psychiatry.
2018;118(3):18‑26. (In Russ.)
https://doi.org/10.17116/jnevro20181183118-26
Objective. To evaluate the efficacy and safety of the interferon beta-1b bioanalogue «infibeta» in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. Material and methods. The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS. Results. In all groups, there was a significant decrease in the AARR and an increase in the EDSS score (p<0,05) after 12 and 24 months of treatment (p<0,05) with the best indicators in groups 1—3. After 12 months of treatment, the number of patients without signs of MRI activity was higher in groups 1—3 (48—61%) than in groups 4 and 5 (47, 43%, respectively) (p>0,05). After 24 months of treatment, the number of patients without signs of MRI activity decreased to 41–46% in groups 1—3, and more significantly in group 4 (27%). The percentage of NEDA-3 achieving patients did not significantly differ in the groups (23—32%) after 12 months of treatment. After 24 months of treatment the NEDA-3 declined more in group 4 (19%), least of all in groups 1 and 2 (27, 25%, respectively) (p>0,05). In most cases, the observed adverse events were mild or moderate. Flu-like syndrome was observed rarely in groups 1 and 4 (p<0,05). Injection reactions were observed most commonly in groups 3 and 5 (p<0,05). Conclusion. Infibeta, while retaining all the advantages of high-dose interferon beta, has the best tolerability profile, which makes it one of the optimal first line disease-modifying therapy for treatment of patients with MS.
Authors:
Khabirov F.A.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Khaĭbullin T.I.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Granatov E.V.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Shakirzianova S.R.
GAUZ «Republic clinical neurology center», Kazan, Russia
Babicheva N.N.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Kochergina O.S.
Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia
Rakhmatullina E.F.
Neurology and manual therapy department of state medical academy, Kazan, Russia
Akhmedova G.M.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Aver'ianova L.A.
Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'
Yakupov M.A.
Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia
Sabirov Zh.F.
Republican clinical diagnostic center for demyelinating diseases of the Ministry of Health of the Republic of Tatarstan GAUZ «Republic clinical neurology center», Kazan, Russia
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.